Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study - Pfützner, A; Hanefeld, M; Lübben, G; Weber, M M; Karagiannis, E; Köhler, C; Hohberg, C; Forst, T (Hormone and Metabolic Research, 2007)